DMT1 (Divalent Metal Transporter 1), also known as SLC11A2 or NRAMP2, is a proton-coupled metal ion transporter located on the apical membrane of duodenal enterocytes that mediates the absorption of ferrous iron (Fe2+) and other divalent metals from the intestinal lumen into the cytoplasm. It represents the rate-limiting step in dietary iron absorption and is regulated by cellular iron status through the IRP/IRE post-transcriptional control system.
Think of DMT1 as a subway turnstile that only lets passengers through if they have the right ticket β except the "ticket" is an H+ ion (proton), and the "passenger" is an Fe2+ ion. The turnstile sits at street level (the intestinal lumen) where people queue to enter the underground system (the enterocyte).
This turnstile is picky: it only accepts coins in the correct denomination β ferrous iron (Fe2+), not ferric iron (Fe3+). That's why the environment needs to be acidic (lots of H+ ions floating around) β it's like having plenty of small change available. When you pop an antacid or take a proton pump inhibitor, you're essentially removing all the coins from circulation, so even if iron shows up, the turnstile won't budge.
Now imagine someone blocking the turnstile entrance with their luggage β that's lactoferrin from dairy. Even if you have the right ticket and coins, you physically can't get through. Once iron makes it through the turnstile into the cell, it has two options: get stored in a locker (ferritin) or continue to the exit on the other side of the building (ferroportin) to reach the bloodstream. The number of turnstiles installed depends on how desperate the system is for passengers β in iron deficiency, the station installs extra turnstiles (upregulates DMT1); in iron overload, it boards them up.
DMT1 operates through a proton-coupled active transport mechanism:
Molecular structure and location:
- 12 transmembrane domain protein (561 amino acids)
- Located on apical (brush border) membrane of duodenal enterocytes
- Also expressed in proximal jejunum (declining gradient)
- Alternative splicing produces +IRE and -IRE isoforms (IRE = Iron Responsive Element in 3' UTR)
Transport mechanism:
- H+/Fe2+ symport: DMT1 binds one H+ ion and one Fe2+ ion simultaneously
- Conformational change: Proton gradient (luminal pH ~6.0 vs cytoplasmic pH ~7.2) drives inward transport
- Release: Both ions released into cytoplasm
- Reset: Transporter returns to outward-facing conformation
Substrate specificity:
- Primary: Fe2+ (ferrous iron)
- Secondary: Mn2+, Co2+, Zn2+ (lower affinity)
- Toxic: Cd2+, Pb2+ (unfortunately also transported)
- Does NOT transport: Fe3+ (ferric iron) β must be reduced by vitamin C (ascorbic acid) or duodenal cytochrome B (DcytB) first
Regulatory cascade:
graph TD
A[Low cellular iron] --> B[IRP1/IRP2 activation]
B --> C[IRPs bind IRE in DMT1 mRNA 3' UTR]
C --> D[mRNA stabilization]
D --> E["β DMT1 protein translation"]
E --> F["β Iron absorption"]
G[High cellular iron] --> H[IRP1/IRP2 inactivation]
H --> I[IRE unbound]
I --> J[mRNA degradation]
J --> K["β DMT1 protein"]
K --> L["β Iron absorption"]
M["Hepcidin β"] --> N[Ferroportin degradation]
N --> O[Iron trapped in enterocyte]
O --> P[Enterocyte shed after 2-3 days]
P --> Q[Iron lost in feces]
Post-translational regulation:
- Hepcidin does NOT directly act on DMT1 (acts on ferroportin instead)
- However, hepcidin-induced ferroportin degradation traps iron in enterocytes, indirectly reducing DMT1 expression over 24-48h
- Hypoxia-inducible factor 2Ξ± (HIF2Ξ±) upregulates DMT1 transcription in response to low systemic oxygen
Intracellular iron trafficking after DMT1:
- Fe2+ enters cytoplasm via DMT1
- Either: stored as ferritin (apoferritin captures Fe2+ β ferric core formation)
- Or: transported to basolateral membrane β exported via ferroportin β oxidized to Fe3+ by hephaestin or ceruloplasmin β binds transferrin in blood
DMT1 function is clinically relevant in multiple cPNI contexts:
Iron deficiency and anemia:
- Patients with hypochlorhydria (chronic PPI use, atrophic gastritis, H. pylori infection) have impaired DMT1 function due to elevated intestinal pH (>7.0 prevents Fe3+βFe2+ reduction)
- Clinical threshold: gastric pH >4.0 significantly reduces iron bioavailability
- Genetic DMT1 mutations (rare) cause microcytic hypochromic anemia unresponsive to oral iron supplementation (Belgrade rat model in humans)
Evolutionary mismatch:
- DMT1 evolved in context of low dietary iron availability (pre-agricultural diet ~15-30mg/day, absorption rate 10-15%)
- Modern diets with fortified cereals + heme iron from meat can overwhelm regulatory capacity in genetically susceptible individuals β iron overload risk
- This relates to Metamodel 3 (Metabolic Flexibility): the system expects intermittent iron availability, not constant high intake
Lactoferrin blockade as therapeutic strategy:
- Lactoferrin (from dairy or supplementation) competitively blocks DMT1 β reduces iron absorption by ~40-60%
- Clinically useful in: (1) iron overload conditions (hemochromatosis adjunct), (2) acute infections where restricting iron from pathogens aids immunity, (3) inflammatory bowel disease where mucosal iron accumulation worsens oxidative stress
- Contraindicated in: iron deficiency anemia, pregnancy, children
Selfish Immune System interaction:
Assessment and intervention:
- Evaluate DMT1 function indirectly through: (1) gastric pH testing, (2) ferritin + transferrin saturation + serum iron, (3) oral iron absorption test (50mg ferrous sulfate β measure serum iron at 2h, expect β50-100 ΞΌg/dL)
- Interventions to enhance DMT1 function: vitamin C 200mg with meals (keeps iron reduced), betaine HCl if hypochlorhydric, avoid calcium/zinc/tea with iron-rich meals (competitive inhibition)
- Interventions to reduce DMT1 function: lactoferrin 100-300mg, calcium carbonate 500mg with meals, increase dietary phytate (from whole grains)
Heavy metal toxicity:
- DMT1 also transports Pb2+ and Cd2+ β lead poisoning risk in iron-deficient children (upregulated DMT1 = β lead absorption)
- Public health implication: iron deficiency increases environmental toxin burden
- Transport stoichiometry: 1 H+ : 1 Fe2+ symport (electroneutral)
- Optimal pH: 5.5-6.5 for maximal activity (duodenal lumen post-gastric emptying)
- Expression regulation: +IRE isoform mRNA half-life increases 5-fold in iron deficiency (from ~30min to ~150min)
- Dietary iron intake: average Western diet 10-20mg/day, typical absorption 1-2mg/day (5-10% bioavailability)
- Competitive inhibition: calcium >300mg, zinc >15mg, polyphenols (tea/coffee) reduce DMT1-mediated iron absorption by 40-90%
- Lactoferrin IC50: ~50ΞΌg/mL blocks DMT1 activity by 50% (achievable with 100mg oral lactoferrin supplementation)
- Genetic mutations: G185R mutation in SLC11A2 gene causes severe microcytic anemia (autosomal recessive)
- Enterocyte lifespan: 2-3 days β iron trapped by hepcidin-degraded ferroportin is lost when cell sheds into lumen
- Hepcidin response time: IL-6 elevation β hepcidin synthesis within 6h β ferroportin degradation within 12-24h β DMT1 downregulation (indirect) within 48-72h
- Heavy metal affinity: Pb2+ Km ~2ΞΌM, Cd2+ Km ~5ΞΌM (vs Fe2+ Km ~0.5ΞΌM) β lower affinity but still clinically significant
- iron β primary substrate transported from gut lumen to cytoplasm
- ferroportin β works sequentially with DMT1; DMT1 = apical import, ferroportin = basolateral export
- enterocytes β cell type where DMT1 is predominantly expressed on apical surface
- lactoferrin β competitive inhibitor that physically blocks DMT1 substrate binding
- ferritin β intracellular storage protein for iron after DMT1 transport
- vitamin C β reduces Fe3+ to Fe2+ in lumen, making iron available for DMT1 uptake
- hepcidin β indirectly regulates DMT1 by degrading ferroportin, trapping iron in enterocytes
- IL-6 β triggers hepcidin synthesis during inflammation, leading to DMT1 downregulation
- PPI β proton pump inhibitors raise intestinal pH, impairing DMT1 function
- iron absorption β DMT1 is the rate-limiting step in this process
- duodenum β primary anatomical location of DMT1-mediated iron uptake
- inflammatory anaemia β caused by hepcidin-mediated suppression of DMT1-ferroportin axis
- H. pylori β infection causes hypochlorhydria, reducing DMT1 efficiency
- transferrin β accepts iron in bloodstream after ferroportin export and oxidation
- hypoxia β induces HIF2Ξ±, which upregulates DMT1 transcription
- IRP β iron regulatory proteins that control DMT1 mRNA stability via IRE binding
- Metamodel 3 β DMT1 regulation exemplifies metabolic flexibility and iron homeostasis
- Selfish Immune System β immune system uses hepcidin to restrict iron via DMT1-ferroportin axis during infection
- phytate β chelates iron in lumen, reducing Fe2+ availability for DMT1
- Chronic Kidney Disease β often presents with hepcidin elevation β functional iron deficiency despite adequate stores
- AGEs β advanced glycation end products impair DMT1 trafficking in diabetes
- butyrate β upregulates DMT1 expression via histone deacetylase inhibition in colonocytes (minor role)
- zinc β competitive substrate for DMT1, high zinc intake impairs iron absorption